These subgroup analyses add to the existing evidence of bempedoic acid as an effective treatment for the reduction of cardiovascular risk. MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH ...

This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...

Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on ...

Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study. Ryan Haumschild, PharmD, MS, MBA: Can you please review the rationale and study design of the 5-year ...

Objective To evaluate sex differences in perioperative characteristics, in-hospital outcomes and long-term survival following coronary artery bypass grafting (CABG).Methods Prospective data were ...

Gemcitabine-iDRS did not show superior bladder-intact event-free survival over chemoradiotherapy and there were no patient subgroups that suggest further evaluation in subsequent studies.

The MarketWatch News Department was not involved in the creation of this content.-- Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was ...